Business Context and Reporting Period
Company: Neuralstem, Inc. (Note: Request metadata referenced "Palisade Bio, Inc.", but the filing text identifies the registrant as Neuralstem, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2017
Reporting Period: Three and six months ended June 30, 2017
Context: The Company reported financial results and provided updates on clinical programs and business highlights via a press release attached as Exhibit 99.01.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.01) for detailed data. The text itself does not contain specific numerical values for the following metrics:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or quantify material changes versus the prior comparable period. It only indicates that results for the three and six months ended June 30, 2017, were reported.
Guidance, Outlook, and Risks
- Outlook/Updates: The Company provided an update on clinical programs and business highlights, though specific details are contained in the referenced Exhibit 99.01.
- Legal Disclaimer: Information furnished under Item 2.02 and Exhibit 99.01 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liability of such section.
- Risks/Contingencies: No specific risks or contingencies are detailed in the cover text.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.01) as they are not present in the 8-K cover text.
- Review the clinical program updates and business highlights detailed in the press release for operational progress.
- Confirm the distinction between the metadata company name ("Palisade Bio, Inc.") and the actual registrant ("Neuralstem, Inc.") to ensure correct entity analysis.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act per the disclaimer in Item 2.02.